HIV-1 Vaccine Trial Results
Author Information
Author(s): Churchyard Gavin J., Morgan Cecilia, Adams Elizabeth, Hural John, Graham Barney S., Moodie Zoe, Grove Doug, Gray Glenda, Bekker Linda-Gail, McElrath M. Juliana, Tomaras Georgia D., Goepfert Paul, Kalams Spyros, Baden Lindsey R., Lally Michelle, Dolin Raphael, Blattner William, Kalichman Artur, Figueroa J. Peter, Pape Jean, Schechter Mauro, Defawe Olivier, De Rosa Stephen C., Montefiori David C., Nabel Gary J., Corey Lawrence, Keefer Michael C.
Primary Institution: Aurum Institute for Health Research, Klerksdorp, South Africa
Hypothesis
The study aims to evaluate the safety and immunogenicity of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults.
Conclusion
The vaccine regimen was well-tolerated and induced polyfunctional CD4+ and CD8+ T-cells and multi-clade anti-Env binding antibodies.
Supporting Evidence
- The vaccine was well tolerated and safe.
- T-cell responses were observed in 70.8% of vaccine recipients.
- Binding antibody responses to consensus Group M and Clades A, B, and C were high.
- Adverse events were similar between vaccine and placebo groups.
- Participants were monitored for 12 months after enrollment.
- Immunogenicity was evaluated using various assays.
- Pre-existing Ad5 neutralizing antibodies affected T-cell responses.
- The study was conducted across diverse geographic regions.
Takeaway
Researchers tested a new HIV vaccine on healthy adults and found it was safe and helped the body make important immune cells.
Methodology
480 participants were randomized to receive either the vaccine or placebo, monitored for adverse events, and evaluated for immune responses.
Potential Biases
Potential bias due to the high prevalence of pre-existing Ad5 neutralizing antibodies in the South African cohort.
Limitations
The effect of pre-existing Ad5 neutralizing antibodies on HIV-specific T-cell responses was not determined for all participants.
Participant Demographics
Participants were aged 18-50, healthy, and included individuals from South Africa, the United States, and Latin America.
Statistical Information
P-Value
0.035
Confidence Interval
95% CI 83.1%–91.5%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website